Aerospace Plastics Market Size, Share & Trends Analysis Report By Product (PEEK, PPSU, PC, PEI, PMMA, PA, PPS, PAI, PPE, PU, Others), By Application, By End-use, By Region And Segment Forecasts, 2022 - 2030

Aerospace Plastics Market Size, Share & Trends Analysis Report By Product (PEEK, PPSU, PC, PEI, PMMA, PA, PPS, PAI, PPE, PU, Others), By Application, By End-use, By Region And Segment Forecasts, 2022 - 2030

Aerospace Plastics Market Growth & Trends

The global aerospace plastics market size is expected to reach USD 13.63 billion by 2030, registering CAGR of 8.5% during the forecast period, according to a new report by Grand View Research, Inc. Non-corrosive nature and high-temperature resistance of plastics are the factors expected to bolster market growth the forecast period.

Aerospace plastics exhibit high strength and heat resistance properties. Its high elasticity strength aids in the production of various aircraft components such as empennage, airframe, and fuselage. In addition, plastics are lightweight yet high-performance alternatives to metals such as steel and aluminum; as a result, the market is expected to grow significantly.

Easy adoption in aircraft designs coupled with high durability and chemical resistance offered by the product is expected to drive market during the forecast period. However, the components manufactured with the use of plastic polymers are hard to inspect for flaws, leading to quality variations and defects, resulting in increased incidents of plastic fracture. This leads to high operating repair and maintenance costs, which are posing a threat to aerospace plastics market growth.

Aerospace plastics provide a high degree of freedom in designing of the complicated components of an aircraft that results into an increase in the percentage of material utilization in manufacturing military and commercial aircraft significantly during the past couple of decades. This has bolstered the demand for plastics in aerospace applications.

Commercial aircraft manufacturers are entering into supplier agreements with plastic resins & composite manufacturers to develop a reliable supply channel for their aircraft components. In November 2020, Boeing awarded a long-term enterprise agreement to Solvay for supplying advanced materials such as adhesives, surfacing films, and thermoplastic & thermoset, composites for aircraft interior section, secondary structures, and primary structures.

Aerospace Plastics Market Report Highlights

  • Cabin interiors dominated the application segment and accounted for more than 30.0% share of the overall revenue in 2021. The growing use of plastics in seat & seating components, cabin dividers, overhead cabins, and other interior components for improving the appearance of the cabin. This is attributed to its flexibility, impact strength, high-temperature resistance, and corrosion resistance similar to metals
  • Commercial & freighter aircraft accounted for majority of the revenue share. The rapid growth in the air passenger traffic has led to the increased production of commercial aircraft, which in turn is expected to bolster demand for the plastics
  • North America accounted for more than 58.0% share of the global revenue in 2021. The growing demand for commercial aircraft coupled with the presence of Boeing, a leading manufacturer of aircraft is expected to drive demand for the aerospace polymers in the region
  • The market is fragmented wherein the global players adopt various marketing and pricing strategies to gain market share and acquire the business from major aircraft manufacturers such as Airbus, Boeing, and Lockheed Martin
  • In November 2021, Solvay collaborated with Switzerland-based OEM 9T Labs AG to produce low-to-medium size aerospace parts. This collaboration aims at producing carbon reinforced polyphenylene sulfide, polyamide, and polyetheretherketone composite materials for aircraft components
Please note The report will be delivered in 4-8 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Research Methodology
1.3.1. Information Procurement
1.3.1.1. Purchased database
1.3.1.2. GVR’s internal database
1.3.2. Primary Research
1.4. Research Scope and Assumptions
1.5. List to Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. AI in Oncology Market
Chapter 3. AI in Oncology Market Variables, Trends, & Scope
3.1. Penetration and Growth Prospect Mapping
3.2. Market Dynamics
3.3. AI in Oncology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.3. Impact of COVID-19 on the market
Chapter 4. Chapter 5 AI in Oncology Market: Component Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. AI in Oncology Market: Component Movement Analysis, 2021 & 2030 (USD Million)
4.3. Software Solutions
4.3.1. Software Solutions market estimates and forecasts, 2016 - 2030 (USD Million)
4.4. Hardware
4.4.1. Hardware market estimates and forecasts, 2016 - 2030 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2016 - 2030 (USD Million)
Chapter 5. AI in Oncology Market: Cancer Type Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. AI in Oncology Market: Cancer Type Movement Analysis, 2021 & 2030 (USD Million)
5.3. Breast Cancer
5.3.1. Breast Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.4. Lung Cancer
5.4.1. Lung Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.5. Prostate Cancer
5.5.1. Prostate Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.6. Colorectal Cancer
5.6.1. Colorectal Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.7. Brain Tumor
5.7.1. Brain Tumor market estimates and forecasts, 2016 - 2030 (USD Million)
5.8. Others
5.8.1. Others market estimates and forecasts, 2016 - 2030 (USD Million)
Chapter 6. AI in Oncology Market: Treatment Type Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. AI in Oncology Market: Treatment Type Movement Analysis, 2021 & 2030 (USD Million)
6.3. Chemotherapy
6.3.1. Chemotherapy market estimates and forecasts, 2016 - 2030 (USD Million)
6.4. Radiotherapy
6.4.1. Radiotherapy market estimates and forecasts, 2016 - 2030 (USD Million)
6.5. Immunotherapy
6.5.1. Immunotherapy market estimates and forecasts, 2016 - 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2016 - 2030 (USD Million)
Chapter 7. AI in Oncology Market: Regional Estimates & Trend Analysis
7.1. Regional Market Snapshot
7.2. AI in Oncology Market: Regional Movement Analysis
7.3. North America
7.3.1. North America market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.3.2. North America market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.3.3. North America market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.3.4. U.S.
7.3.4.1. U.S. market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.3.4.2. U.S. market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.3.4.3. U.S. market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.3.5. Canada
7.3.5.1. Canada market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.3.5.2. Canada market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.3.5.3. Canada market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4. Europe
7.4.1. Europe market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.2. Europe market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.3. Europe market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4.4. Germany
7.4.4.1. Germany market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.4.2. Germany market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.4.3. Germany market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4.5. U.K.
7.4.5.1. U.K. market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.5.2. U.K. market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.5.3. U.K. market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4.6. France
7.4.6.1. France market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.6.2. France market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.6.3. France market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4.7. Italy
7.4.7.1. Italy market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.7.2. Italy market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.7.3. Italy market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4.8. Spain
7.4.8.1. Spain market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.8.2. Spain market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.8.3. Spain market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4.9. Russia
7.4.9.1. Russia market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.4.9.2. Russia market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.4.9.3. Russia market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.5.2. Asia Pacific market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.5.3. Asia Pacific market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5.4. Japan
7.5.4.1. Japan market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.5.4.2. Japan market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.5.4.3. Japan market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5.5. China
7.5.5.1. China market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.5.5.2. China market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.5.5.3. China market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5.6. India
7.5.6.1. India market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.5.6.2. India market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.5.6.3. India market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5.7. Australia
7.5.7.1. Australia market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.5.7.2. Australia market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.5.7.3. Australia market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5.8. South Korea
7.5.8.1. South Korea market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.5.8.2. South Korea market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.5.8.3. South Korea market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.6.2. Latin America market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.6.3. Latin America market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.6.4. Brazil
7.6.4.1. Brazil market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.6.4.2. Brazil market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.6.4.3. Brazil market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.6.5. Mexico
7.6.5.1. Mexico market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.6.5.2. Mexico market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.6.5.3. Mexico market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.6.6. Argentina
7.6.6.1. Argentina market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.6.6.2. Argentina market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.6.6.3. Argentina market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.7. MEA
7.7.1. MEA market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.7.2. MEA market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.7.3. MEA market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.7.4. South Africa
7.7.4.1. South Africa market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.7.4.2. South Africa market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.7.4.3. South Africa market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.7.5.2. Saudi Arabia market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.7.5.3. Saudi Arabia market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.7.6. UAE
7.7.6.1. UAE market estimates and forecasts, by component 2016 - 2030 (USD Million)
7.7.6.2. UAE market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
7.7.6.3. UAE market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
Chapter 8. AI in Oncology Market - Competitive Analysis
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Competition Categorization
8.3. Company Market Position Analysis
Chapter 9. Competitive Landscape: Company Profiles
9.1. Azra AI
9.1.1. Company overview
9.1.2. Financial performance
9.1.3. Product benchmarking
9.1.4. Strategic initiatives
9.2. IBM
9.2.1. Company overview
9.2.2. Financial performance
9.2.3. Product benchmarking
9.2.4. Strategic initiatives
9.3. Siemens Healthineers
9.3.1. Company overview
9.3.2. Financial performance
9.3.3. Product benchmarking
9.3.4. Strategic initiatives
9.4. Intel
9.4.1. Company overview
9.4.2. Financial performance
9.4.3. Product benchmarking
9.4.4. Strategic initiatives
9.5. GE Healthcare
9.5.1. Company overview
9.5.2. Financial performance
9.5.3. Product benchmarking
9.5.4. Strategic initiatives
9.6. NVIDIA
9.6.1. Company overview
9.6.2. Financial performance
9.6.3. Product benchmarking
9.6.4. Strategic initiatives
9.7. Digital Diagnostics Inc.
9.7.1. Company overview
9.7.2. Financial performance
9.7.3. Product benchmarking
9.7.4. Strategic initiatives
9.8. Concert.AI
9.8.1. Company overview
9.8.2. Financial performance
9.8.3. Product benchmarking
9.8.4. Strategic initiatives
9.9. Median Technologies
9.9.1. Company overview
9.9.2. Financial performance
9.9.3. Product benchmarking
9.9.4. Strategic initiatives
9.10. Path AI
9.10.1. Company overview
9.10.2. Financial performance
9.10.3. Product benchmarking
9.10.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings